Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bvlgari and the University of Oxford’s Jenner Institute announce the next stage of their pledge to build a pandemic-free future by awarding the inaugural Bvlgari Scholarships.

Bvlgari Scholars Rebecca Makinson and Cameron Bissett outside the Big Data Institute Building © John Cairns
Bvlgari Scholars Rebecca Makinson and Cameron Bissett

Following the announcement in June of a new philanthropic relationship between Bvlgari and the University of Oxford, Bvlgari’s donation in support of DPhil students in vaccine research benefits two exceptional students, appointed as the first cohort of Bvlgari Scholars. The Jenner Institute welcomes students Cameron Bissett and Rebecca Makinson this month for the start of their DPhil courses, after demonstrating remarkable academic potential and merit in the field of vaccine-related immunology.

Oxford’s Professor of Vaccinology Sarah Gilbert, who joined Bvlgari CEO Jean-Christophe Babin in June to announce the brand’s donation during a live webinar, said: ‘We are very grateful to Bvlgari who have enabled Cameron and Rebecca to focus on their vital research free from financial worry. I hope these students are the first of many more future cohorts of Bvlgari Scholars.’

Reaching headlines across the globe for their vaccine candidate for COVID-19, Oxford’s Jenner Institute is a world-leading vaccine development group, designing, manufacturing and testing many novel vaccine technologies.

The full story is available on The Jenner Institute website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.